Cargando…
Discovery and Validation of Hypermethylated Markers for Colorectal Cancer
Colorectal carcinoma (CRC) is one of the most prevalent malignant tumors worldwide. Screening and early diagnosis are critical for the clinical management of this disease. DNA methylation changes have been regarded as promising biomarkers for CRC diagnosis. Here, we map DNA methylation profiling on...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4963574/ https://www.ncbi.nlm.nih.gov/pubmed/27493446 http://dx.doi.org/10.1155/2016/2192853 |
_version_ | 1782444971034411008 |
---|---|
author | Wei, Jiufeng Li, Guodong Dang, Shuwei Zhou, Yuhui Zeng, Kai Liu, Ming |
author_facet | Wei, Jiufeng Li, Guodong Dang, Shuwei Zhou, Yuhui Zeng, Kai Liu, Ming |
author_sort | Wei, Jiufeng |
collection | PubMed |
description | Colorectal carcinoma (CRC) is one of the most prevalent malignant tumors worldwide. Screening and early diagnosis are critical for the clinical management of this disease. DNA methylation changes have been regarded as promising biomarkers for CRC diagnosis. Here, we map DNA methylation profiling on CRC in six CRCs and paired normal samples using a 450 K bead array. Further analysis confirms the methylation status of candidates in two data sets from the Gene Expression Omnibus. Receiver operating characteristic (ROC) curves are calculated to determine the diagnostic performances. We identify 1549 differentially methylated regions (DMRs) showing differences in methylation between CRC and normal tissue. Two genes (ADD2 and AKR1B1), related to the DMRs, are selected for further validation. ROC curves show that the areas under the curves of ADD2 and AKR1B1 are higher than that of SEPT9, which has been clinically used as a screening biomarker of CRC. Our data suggests that aberrant DNA methylation of ADD2 and AKR1B1 could be potential screening markers of CRC. |
format | Online Article Text |
id | pubmed-4963574 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-49635742016-08-04 Discovery and Validation of Hypermethylated Markers for Colorectal Cancer Wei, Jiufeng Li, Guodong Dang, Shuwei Zhou, Yuhui Zeng, Kai Liu, Ming Dis Markers Research Article Colorectal carcinoma (CRC) is one of the most prevalent malignant tumors worldwide. Screening and early diagnosis are critical for the clinical management of this disease. DNA methylation changes have been regarded as promising biomarkers for CRC diagnosis. Here, we map DNA methylation profiling on CRC in six CRCs and paired normal samples using a 450 K bead array. Further analysis confirms the methylation status of candidates in two data sets from the Gene Expression Omnibus. Receiver operating characteristic (ROC) curves are calculated to determine the diagnostic performances. We identify 1549 differentially methylated regions (DMRs) showing differences in methylation between CRC and normal tissue. Two genes (ADD2 and AKR1B1), related to the DMRs, are selected for further validation. ROC curves show that the areas under the curves of ADD2 and AKR1B1 are higher than that of SEPT9, which has been clinically used as a screening biomarker of CRC. Our data suggests that aberrant DNA methylation of ADD2 and AKR1B1 could be potential screening markers of CRC. Hindawi Publishing Corporation 2016 2016-07-14 /pmc/articles/PMC4963574/ /pubmed/27493446 http://dx.doi.org/10.1155/2016/2192853 Text en Copyright © 2016 Jiufeng Wei et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Wei, Jiufeng Li, Guodong Dang, Shuwei Zhou, Yuhui Zeng, Kai Liu, Ming Discovery and Validation of Hypermethylated Markers for Colorectal Cancer |
title | Discovery and Validation of Hypermethylated Markers for Colorectal Cancer |
title_full | Discovery and Validation of Hypermethylated Markers for Colorectal Cancer |
title_fullStr | Discovery and Validation of Hypermethylated Markers for Colorectal Cancer |
title_full_unstemmed | Discovery and Validation of Hypermethylated Markers for Colorectal Cancer |
title_short | Discovery and Validation of Hypermethylated Markers for Colorectal Cancer |
title_sort | discovery and validation of hypermethylated markers for colorectal cancer |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4963574/ https://www.ncbi.nlm.nih.gov/pubmed/27493446 http://dx.doi.org/10.1155/2016/2192853 |
work_keys_str_mv | AT weijiufeng discoveryandvalidationofhypermethylatedmarkersforcolorectalcancer AT liguodong discoveryandvalidationofhypermethylatedmarkersforcolorectalcancer AT dangshuwei discoveryandvalidationofhypermethylatedmarkersforcolorectalcancer AT zhouyuhui discoveryandvalidationofhypermethylatedmarkersforcolorectalcancer AT zengkai discoveryandvalidationofhypermethylatedmarkersforcolorectalcancer AT liuming discoveryandvalidationofhypermethylatedmarkersforcolorectalcancer |